Clinical trial NCT05142410: Understanding Post-translational Modifications to Circulating Histones Via Mass Spectrometry in Pregnant Women Developing Pre-eclampsia: A Retrospective Study
Official title: A Retrospective Study Using Mass Spectrometry to Characterize Post-translational Modifications to Circulating Histones in Pregnant Women Developing Pre-eclampsia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy Related
Pre-Eclampsia
Keywords: Pregnancy
Pre-eclampsia
Histones
Mass spectrometry
Neutrophils
Extracellular traps
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-12-02
Enrollment: 28
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study is based on frozen plasma samples from pregnant women, taken at the time of them giving birth from among the 50 women who constituted the GrossPath cohort. Fourteen of these women had had normal pregnancies and fourteen had developed pre-eclampsia. Cases are matched on maternal age, clinical event (delivery) and gestational age will be included from the GrossPath cohort.

Brief summary: This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47).

Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine.

Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications.

The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies.

The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.


Eligibility criteria: Inclusion Criteria:

* Not applicable as this study is on samples from a biobank. The inclusion criteria for the "GrossPath" cohort were:
* pregnant women followed at Nîmes University hospital for normal pregnancy or pregnancy with placental vascular pathology (pre-eclampsia and/or intra-uterine growth retardation).
* The patient must have given her free and informed consent and signed the consent form.
* The patient must be a member or beneficiary of a health insurance plan
* Only women are included
* Patients are at least 18 years old

Exclusion Criteria:

* Not applicable as this is a study on samples from a biobank. The non-inclusion criteria of the "GrossPath" cohort were :
* twin pregnancies.

Primary outcomes:
measure: Presence of methylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
Secondary outcomes:
measure: Intensity of methylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H2A in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H2B in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H3 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H4 in pregnant women with normal pregnancies
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia
timeFrame: At pregnancy term (max 41 weeks gestation)
measure: Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 of pregnancy
measure: Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: After 34 weeks of pregnancy
measure: Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 of pregnancy
measure: Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
timeFrame: 34 to 41 weeks of pregnancy
measure: Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
timeFrame: Before 34 weeks of pregnancy
measure: Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
timeFrame: 34 to 41 weeks of pregnancy
measure: Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
timeFrame: Before 34 weeks of pregnancy
measure: Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
timeFrame: 34 to 41 weeks of pregnancy
Other outcomes:
Locations:
city: Nîmes
country: France
facility: Nîmes University Hospital
state: Gard
Study officials:
affiliation: Nîmes University Hospital
name: Sylvie BOUVIER, Dr.
role: PRINCIPAL_INVESTIGATOR
References: